<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Human plasma-derived von Willebrand factor (contains factor VIII): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Human plasma-derived von Willebrand factor (contains factor VIII): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Human plasma-derived von Willebrand factor (contains factor VIII): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8782" href="/d/html/8782.html" rel="external">see "Human plasma-derived von Willebrand factor (contains factor VIII): Drug information"</a> and <a class="drug drug_patient" data-topicid="11523" href="/d/html/11523.html" rel="external">see "Human plasma-derived von Willebrand factor (contains factor VIII): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3000299"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alphanate;</li>
<li>Alphanate/VWF Complex/Human [DSC];</li>
<li>Humate-P;</li>
<li>Wilate</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868789"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Humate-P;</li>
<li>Wilate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F3958727"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F3000409"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Antihemophilic factor/von Willebrand factor complex (human) is a combination product that contains both factor VIII and von Willebrand factor. Dosing should be calculated based on the units of factor VIII for hemophilia A and calculated based on units of von Willebrand factor present for von Willebrand disease. <b></b>Products are not identical and should not be used interchangeably.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41bca916-fbad-4b58-b634-e51fe53bc8d4">Hemophilia A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A (Factor VIII deficiency):</b> Individualize dosage based on clinical response and factor VIII activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2% of normal. Patients with inhibitory antibodies to factor VIII may require higher doses, more frequent administration, and/or selection of alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control and prevention of bleeding episodes or perioperative management: Note: </b>Dosage is expressed in units of factor VIII activity and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, individualized incremental recovery using factor VIII activity assays, and clinical situation of patient. Guidelines do not specify a preferred agent; see product-specific labeling for approved ages and indications.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Formula for units required to raise blood level:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Number of Factor VIII Units required = body weight (in kg) x 0.5 units/kg per units/dL x desired factor VIII level increase (units/dL or %)</p>
<p style="text-indent:-2em;margin-left:10em;">For example, for a desired 100% level in a 25 kg patient who has an actual level of 20%: Number of Factor VIII Units needed = 25 kg x 0.5 units/kg per units/dL x 80% = 1,000 units</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>):</i>
<b>Note:</b> Factor VIII level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent IV: Infants, Children, and Adolescents: The following recommendations reflect World Federation of Hemophilia (WFH) guidelines for higher dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels (if available) before the next dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor VIII Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>a</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. Life-threatening hemorrhages may require every-8-hour dosing.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours; more frequent doses (every 8 hours) may be needed for life-threatening bleeding</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours; more frequent doses (every 8 hours) may be needed for life-threatening bleeding</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 80% to 100%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 60% to 80%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis: Note:</b> Maintain factor VIII trough levels &gt;3% to 5% or higher as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Product-specific dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Wilate: Children ≥12 years and Adolescents: IV: 20 to 40 units/kg/dose every 2 to 3 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Guideline dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>)</i>
<i>:</i>
<b>Note: </b>Dose should be individualized; dose intensity should take into account disease severity, patient's activity and lifestyle and pharmacokinetic properties of product and should be adjusted if breakthrough bleeding occurs. See guidelines for in-depth discussion of risks and benefits of each approach. Guidelines do not specify a preferred agent; see product specific labeling for approved ages and indications.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:10em;">High dose: 25 to 40 units/kg/dose every 2 days.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermediate dose: 15 to 25 units/kg/dose 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Low dose: 10 to 15 units/kg/dose 2 to 3 times weekly. <b>Note:</b> Low dose prophylaxis may be used in young patients as initial therapy to allow patients and families to gradually adjust to prophylaxis and improve adherence; close monitoring is required since patients are at a higher risk for bleeding until escalation occurs.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88226ba2-1c02-44fb-b184-361bea2bbba0">von Willebrand disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>von Willebrand disease (VWD), treatment:</b>
<b>Dosage is expressed in international units of von Willebrand factor: Ristocetin cofactor (VWF:RCo):</b> Dose must be individualized based on type of VWD, extent and location of bleeding, clinical status of patient, and coagulation studies performed prior to and at regular intervals during treatment. For major bleeds where repeated dosing is required, monitor and maintain the FVIII plasma concentration as described for the treatment of hemophilia A. Products are not identical and should not be used interchangeably (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemorrhage, treatment:</b> Product-specific dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Humate P:</b></i> Infants, Children, and Adolescents: <b>Note:</b> In general, administration of 1 unit/kg of factor VIII would be expected to raise circulating VWF:RCo ~5 units/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">General dosing: IV: VWF:RCo 40 to 80 units/kg/dose every 8 to 12 hours; adjust based on extent and location of hemorrhage.</p>
<p style="text-indent:-2em;margin-left:8em;">Dosing based on Von Willebrand type and hemorrhage severity:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Type 1, mild VWD (baseline VWF:RCo activity typically &gt;30%):</b> Minor hemorrhage (if desmopressin is known or suspected to be inadequate) or major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, traumatic hemorrhage): </i>IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Loading dose: VWF:RCo 40 to 60 units/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: VWF:RCo 40 to 50 units/kg/dose every 8 to 12 hours for 3 days to maintain VWF:RCo nadir &gt;50%; follow with VWF:RCo 40 to 50 units/kg/dose once daily for up to 7 days.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Type 1, moderate or severe VWD (baseline VWF:RCo activity typically &lt;30%): </b></i>IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Minor hemorrhage (eg, epistaxis, oral bleeding, menorrhagia): VWF:RCo 40 to 50 units/kg/dose for 1 to 2 doses.</p>
<p style="text-indent:-2em;margin-left:10em;">Major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage):</p>
<p style="text-indent:-2em;margin-left:12em;">Loading dose: VWF:RCo 50 to 75 units/kg.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance dose: VWF:RCo 40 to 60 units/kg/dose every 8 to 12 hours for 3 days to maintain VWF:RCo nadir &gt;50%; follow with VWF:RCo 40 to 60 units/kg/dose once daily for up to 7 days.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Types 2 (all variants) and 3 VWD: </b></i>IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Minor hemorrhage (eg, epistaxis, oral bleeding, menorrhagia): VWF:RCo 40 to 50 units/kg/dose for 1 to 2 doses.</p>
<p style="text-indent:-2em;margin-left:10em;">Major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage):</p>
<p style="text-indent:-2em;margin-left:12em;">Loading dose: VWF:RCo 60 to 80 units/kg.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance dose: VWF:RCo 40 to 60 units/kg/dose every 8 to 12 hours for 3 days to maintain VWF:RCo nadir &gt;50%; follow with 40 to 60 units/kg/dose once daily for up to 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Wilate:</i></b> Children ≥5 years and Adolescents: IV: <b>Note:</b> Patients with Type 3 VWD and those with GI bleeding may require higher doses. In general, administration of VWF:RCo 1 unit/kg will increase the plasma VWF activity by ~2 units/dL (or 2% of normal), as demonstrated by the following formulas:</p>
<p style="text-indent:-2em;margin-left:8em;">Dosage (units) based on desired factor VWF:RCo increase (units/dL or % normal)</p>
<p style="text-indent:-2em;margin-left:8em;">Dosage (units) = Body weight (kg) x 0.5 (units/kg per units/dL) x desired VWF:RCo increase (units/dL or % normal)</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Minor hemorrhage:</b> IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Loading dose: VWF:RCo 20 to 40 units/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: VWF:RCo 20 to 30 units/kg/dose every 12 to 24 hours for ≤3 days, keeping the nadir of VWF:RCo and FVIII activity &gt;30%.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Major hemorrhage:</b> IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Loading dose: VWF:RCo 40 to 60 units/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: VWF:RCo 20 to 40 units/kg/dose every 12 to 24 hours for 5 to 7 days, keeping the nadir of VWF:RCo and FVIII activity &gt;50%.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prophylaxis, surgical/procedural:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Alphanate:</b></i> Children ≥7 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Minor surgery/bleeding:</b> IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Preoperative/preprocedure dose: VWF:RCo 75 units/kg as a single dose 1 hour prior to surgery to achieve a target FVIII:C activity level of 40 to 50 units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: VWF:RCo 50 to 75 units/kg/dose every 8 to 12 hours as clinically needed to maintain FVIII:C activity level of 40 to 50 units/dL for 1 to 3 days; do not exceed FVIII:C activity level of 150 units/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Major surgery/bleeding (excluding Type 3 VWD): </b>IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Preoperative/preprocedure dose: VWF:RCo 75 units/kg as a single dose 1 hour prior to surgery to achieve a target FVIII:C activity level of 100 units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: VWF:RCo 50 to 75 units/kg/dose every 8 to 12 hours as clinically needed to maintain FVIII:C activity level of 100 units/dL for at least 3 to 7 days; do not exceed FVIII:C activity level of 150 units/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Humate-P:</b></i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>General dosing recommendations: </i>Whenever possible, the in vivo recovery (IVR) should be calculated and baseline plasma VWF:RCo and FVIII activity should be assessed in all patients prior to surgery. The loading dose may then be calculated using the IVR.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> If the calculated IVR is not available, assume IVR to be 2 unit/dL per units/kg of VWF:RCo administered.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Procedure-specific target VWF:RCo and FVIII:C plasma concentrations and minimum durations:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Oral surgery (extraction of ≤2 nonmolar teeth with no bony involvement): </b></i>IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 50 to 60 units/dL and target peak plasma FVIII:C concentration of 40 to 50 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance: One-half loading dose every 8 hours as needed to maintain trough VWF:RCo concentration ≥30 units/dL up to 3 days postsurgery and trough FVIII:C concentration &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Administer at least one maintenance dose. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Minor surgery: </b></i>IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 50 to 60 units/dL and target peak plasma FVIII:C concentration of 40 to 50 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance: One-half loading dose every 8 hours for at least 48 hours to maintain trough VWF:RCo concentration ≥30 units/dL up to 3 days postsurgery and trough FVIII:C concentration &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Major surgery/Oral surgery (extraction of &gt;2 teeth or &gt;1 impacted wisdom tooth): </b></i>IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 100 units/dL and target peak plasma FVIII:C concentration of 80 to 100 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance: One-half loading dose every 8 hours for at least 72 hours to maintain both trough VWF:RCo and FVIII:C concentrations &gt;50 units/dL for up to 3 days postsurgery and &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Emergency surgery:</i></b> IV: VWF:RCo 50 to 60 units/kg prior to surgery to achieve a target VWF:RCo peak plasma concentration of 100 units/dL; monitor trough coagulation factor levels and administer subsequent doses as needed to maintain FVIII:C activity level of 80 to 100 units/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Wilate:</i></b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>General dosing recommendations:</i> The in vivo recovery (IVR) should be calculated and baseline plasma VWF:RCo activity should be assessed in all patients prior to surgery. The loading dose may then be calculated using the IVR. The formula to calculate the loading dose is as follows:</p>
<p style="text-indent:-2em;margin-left:10em;">Loading dose (units) = [(Target peak VWF:RCo [units/dL] – Baseline VWF:RCo [units/dL]) x weight (kg)] divided by IVR (units/dL per units/kg)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>If the calculated IVR is not available, assume IVR to be 2 units/dL per unit/kg of VWF:RCo administered. If the calculated IVR is &gt;2.5, assume IVR to be 2.5 units/dL per units/kg of VWF:RCo administered.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Procedure-specific dosing and target VWF:RCo concentrations:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Minor surgery (including tooth extraction): </b></i>IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Loading dose: VWF:RCo 30 to 60 units/kg administered within 3 hours prior to surgery to achieve VWF:RCo peak concentration 50% of normal.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance: VWF:RCo 15 to 30 units/kg/dose (or one-half the loading dose) every 12 to 24 hours to maintain VWF:RCo trough concentrations &gt;30% of normal until wound healing is achieved, for up to 3 days. Do not exceed FVIII:C activity concentrations of 250%.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Major surgery:</b></i> IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Loading dose: VWF:RCo 40 to 60 units/kg administered within 3 hours prior to surgery to achieve VWF:RCo peak concentration 100% of normal.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance: VWF:RCo 20 to 40 units/kg/dose (or one-half the loading dose) every 12 hours for the first 24 hours after the start of surgery to maintain VWF:RCo trough concentrations &gt;50% of normal; then may adjust to every 12 to 24 hours to maintain VWF:RCo trough concentrations &gt; 50% of normal and continue until wound healing is achieved, up to 6 days or more. Do not exceed FVIII:C activity concentration of 250%.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084446"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51084447"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F3000410"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8782" href="/d/html/8782.html" rel="external">see "Human plasma-derived von Willebrand factor (contains factor VIII): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be400ab4-381a-4d5e-b65d-e32a52f7ab49">Hemophilia A, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing: </i>IV: </b>Utilize steps 1 to 3 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Determine desired factor VIII peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For patients without inhibitors and receiving emicizumab who experience breakthrough bleeding, antihemophilic factor should be dosed to target the desired peak factor VIII levels outlined in the table as emicizumab is not indicated for treatment of bleeding episodes.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor/von Willebrand Factor Complex (Human) WFH Treatment Recommendations<sup>d</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Type of hemorrhage or surgery</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Lower-dose practice pattern</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Higher-dose practice pattern</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>May be longer if response is inadequate.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>WFH [Srivastava 2020].</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss: </b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial</b>:</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and Neck:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Gastrointestinal:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Calculate dose using desired peak factor VIII level from step 1 and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(desired peak factor VIII level − patient's baseline factor VIII level) × body weight (kg)]/2</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Factor VIII level units are units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Example for 50 kg patient with desired peak factor VIII level of 35 units/dL and baseline factor VIII level of 5 units/dL:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(35 units/dL − 5 units/dL) × 50 kg]/2 = 750 units of factor VIII</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Determine need for repeat dosing based on manufacturer's recommended frequency of repeat dosing. <b>Note:</b> Frequency of administration must also take into consideration subsequent factor VIII activity measurements and the clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor/von Willebrand Factor Complex (Human) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Bleeding event</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="center">
<p style="text-indent:0em;">Major severity</p></th>
<th align="center">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="center">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Alphanate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Humate-P</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;">No recommendation in product labeling</p></td>
<td align="center">
<p style="text-indent:0em;">No recommendation in product labeling</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Wilate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;margin-top:2em;">
<i>
<b>Continuous infusion dosing</b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk). To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Administer an initial bolus to achieve the desired factor VIII level (see steps 1 and 2 under intermittent bolus dosing), then initiate continuous infusion at 2 to 4 units/kg/hour. Adjust dose based on frequent factor assays (at least daily) and calculation of factor VIII clearance at steady-state using the below equations.</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> With infusion dose increases, re-bolus should be considered to achieve target factor VIII level more quickly. See steps 1 and 2 under intermittent bolus dosing to determine re-bolus dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with moderate/severe hemophilia A, without inhibitors:</b></i>
<b>IV: </b>25 to 40 units/kg of factor VIII concentrate every 2 to 3 days. Preferably, dosing should be tailored to ensure trough factor VIII levels of at least 1% and ideally ≥3% to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3571997-7102-4243-a84b-3b8c0ffaa9c9">von Willebrand disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>von Willebrand disease (VWD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosage is expressed in von Willebrand factor:Ristocetin cofactor (VWF:RCo) units. Products are <b>not</b> identical and should <b>not</b> be used interchangeably (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33570647','lexi-content-ref-NHLBI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33570647','lexi-content-ref-NHLBI.1'])">Ref</a></span>). Refer to product-specific information regarding in vivo recovery and VWF:RCo to FVIII ratios.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Treatment and control of bleeding episodes or perioperative management:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing: </i></b></p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Antihemophilic Factor-von Willebrand Factor Complex (Human) Dose According to Clinical Scenario<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="bottom">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Loading dose<sup>b</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">Maintenance dose<sup>b</sup></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">Monitoring</p></th>
<th align="left">
<p style="text-indent:0em;">Therapeutic goal (efficacy)</p></th>
<th align="left">
<p style="text-indent:0em;">Therapeutic goal (safety)</p></th>
<th align="left">
<p style="text-indent:0em;">Treatment duration<sup>c</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>NHLBI 2007.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>If known, utilize prior patient-specific dosing information to tailor initial dosing.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>The duration of therapy can vary for specific types of surgery. Therapy should be individualized based on the patient, type of procedure, and bleeding history.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Minor bleeding or minor surgery</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to 60 VWF:RCo units/kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 to 40 VWF:RCo units/kg every 12 to 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">VWF:RCo and FVIII peak and trough levels at least once</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Trough levels: VWF:RCo and FVIII &gt;50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Peak levels:</p>
<p style="text-indent:0em;">Do not exceed VWF:RCo &gt;200 units/dL</p>
<p style="text-indent:0em;">or</p>
<p style="text-indent:0em;">FVIII &gt;250 to 300 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Major bleeding or major surgery</p></td>
<td align="left">
<p style="text-indent:0em;">40 to 60 VWF:RCo units/kg</p></td>
<td align="left">
<p style="text-indent:0em;">20 to 40 VWF:RCo units/kg every 8 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">VWF:RCo and FVIII peak and trough levels at least daily</p></td>
<td align="left">
<p style="text-indent:0em;">Trough levels: VWF:RCo and FVIII &gt;50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Peak levels:</p>
<p style="text-indent:0em;">Do not exceed VWF:RCo &gt;200 units/dL</p>
<p style="text-indent:0em;">or</p>
<p style="text-indent:0em;">FVIII &gt; 250 to 300 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">7 to 14 days</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Continuous</i></b>
<b>
<i> IV infusion dosing:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Use only products with extended stability information; extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Administer an initial bolus to achieve the desired factor VWF:RCo and FVIII levels (see table under "Intermittent IV Bolus Dosing"), then initiate continuous infusion at 1 to 2 units/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10063997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10063997'])">Ref</a></span>); initial dose is not well established and may differ based on previously known patient-specific response, history of bleeding, and/or type of procedure; refer to institutional protocols. Adjust dose based on frequent VWF:RCo and FVIII levels (at least daily) and calculation of VWF:RCo clearance at steady state using the equations below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10063997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10063997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">VWF:RCo clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor VWF:RCo level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">New infusion rate (VWF:RCo units/kg/hour) = (VWF:RCo clearance in mL/kg/hour) × (desired factor VWF:RCo level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> With infusion dose increases, re-bolus should be considered to achieve target factor VWF:RCo level more quickly. See table under "Intermittent IV Bolus Dosing" for bolus dosing recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Routine</i></b>
<b>
<i> prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with frequent bleeding episodes:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Product-specific dosing:</i> Wilate<i>:</i> 20 to 40 VWF:RCo units/kg 2 to 3 times per week depending on bleeding severity and clinical response.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Off-label dosing: </i>40 to 60 VWF:RCo units/kg once per week, 2 times per week, 3 times per week, or every other day, depending on bleeding severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25930155','lexi-content-ref-18786010','lexi-content-ref-19811543','lexi-content-ref-25688461','lexi-content-ref-30747707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25930155','lexi-content-ref-18786010','lexi-content-ref-19811543','lexi-content-ref-25688461','lexi-content-ref-30747707'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990847"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988107"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F3000354"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (24%; postoperative)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (30%; postoperative)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Postoperative pain (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest tightness (&gt;5%), edema (&gt;5%), facial edema (&gt;1%), peripheral edema (1%), vasodilation (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills (&gt;1%), headache (&gt;1%), pain (&gt;1%), paresthesia (&gt;1%), dizziness (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (&gt;1%), skin rash (&gt;1%), urticaria (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocythemia (4%; exacerbation)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Parvovirus B19 seroconversion (3%; not accompanied by clinical signs of disease)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (&gt;1%), limb pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory distress (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension, phlebitis, pulmonary embolism, subdural hematoma, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Cerebral hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (moderate), increased factor VIII inhibitors</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Pyelonephritis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Abdominal pain, antibody development (neutralizing), arthralgia, bleeding tendency disorder, chest discomfort, cough, dyspnea, fatigue, hemolysis, hemolytic anemia, hypertension, hypervolemia, infusion-site pain, lethargy, shock, sleep disorder, thromboembolic complications</p></div>
<div class="block coi drugH1Div" id="F3000350"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reaction, including anaphylactic or severe systemic reaction to antihemophilic factor or von Willebrand factor or any component of the formulation; hypersensitivity to human plasma derived products (Wilate only).</p></div>
<div class="block war drugH1Div" id="F3000351"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Neutralizing antibodies (inhibitors) may develop to factor VIII or von Willebrand factor, particularly in patients with type 3 (severe) von Willebrand disease. Patients who develop antibodies against von Willebrand factor will not have an effective clinical response to therapy and infusions may result in anaphylactic reactions; these patients should be managed by an experienced physician and alternatives to therapy should be considered. Patients with hemophilia should have an appropriate laboratory assessment if expected factor VIII plasma levels are not attained or if bleeding is not controlled following an adequate dose. Any patient who has an inadequate response to therapy or a severe adverse reaction should be evaluated for the presence of inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity or allergic reactions have been observed, including anaphylaxis and shock (with or without fever). Monitor patients closely during infusion; if allergic symptoms occur, discontinue administration and initiate treatment immediately. Patients experiencing anaphylactic reactions should be evaluated for the presence of inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thromboembolic events have been reported; especially in patients with known risk factors for thrombosis. Risk of thromboembolic events may be increased in female patients, patients with endogenous high concentrations of factor VIII, and in patients who receive continued treatment resulting in an excessive rise in factor VIII activity; monitor concentrations of von Willebrand factor and factor VIII closely. Use with caution and consider antithrombotic measures when treating patients with von Willebrand disease that are at an increased risk for thrombosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasomotor reactions: Rapid administration may result in vasomotor reactions; do not exceed administration rate recommendations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Products vary by preparation method; some final formulations may contain human albumin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood types A, B, and AB: Alphanate and Humate-P contain trace amounts of blood groups A and B isohemagglutinins; use caution when large or frequently repeated doses are given to individuals with blood groups A, B, and AB. Monitor patients for signs of intravascular hemolysis and falling hematocrit; discontinue therapy and consider administration of serologically compatible type O red blood cells if progressive hemolytic anemia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD], theoretically the Creutzfeldt-Jakob disease [CJD]) that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis A and B vaccination is recommended for all patients receiving plasma derivatives.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Dosage requirements will vary in patients with factor VIII inhibitors; optimal treatment should be determined by the extent of bleeding, presence of inhibitors, and clinical response. Frequency of use is determined by the severity of the disorder or bleeding pattern.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878704"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Formation of factor VIII inhibitors (neutralizing antibodies to AHF human) may occur, particularly in patients with Type 3 (severe) von Willebrand disease; reported overall incidence is 3% to 52%; an increase of inhibitor antibody concentration is seen at 2 to 7 days, with peak concentrations at 1 to 3 weeks after therapy; children &lt;5 years of age may also be at greatest risk. Patients who develop antibodies (usually antibody concentration &gt;10 Bethesda units/mL) against von Willebrand factor will not have an effective clinical response to therapy and infusions may result in anaphylactic reactions; these patients should be managed by an experienced physician and alternatives to therapy should be considered. Any patient who has an inadequate response to therapy or a severe adverse reaction should be evaluated for the presence of inhibitors.</p></div>
<div class="block dosfc drugH1Div" id="F25573581"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Strengths expressed with approximate values.  Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block geq drugH1Div" id="F3000444"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F21121602"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Wilate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500-500 unit (Price provided is per AHF Unit): $2.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000-1000 unit (Price provided is per AHF Unit): $2.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Alphanate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $1.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $1.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $1.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $1.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $1.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Humate-P Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250-600 unit (Price provided is per AHF Unit): $1.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500-1200 unit (Price provided is per AHF Unit): $1.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000-2400 unit (Price provided is per AHF Unit): $1.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868790"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humate-P: FVIII 250 units and VWF:RCo 600 units (1 ea); FVIII 1000 units and VWF:RCo 2400 units (1 ea); FVIII 500 units and VWF:RCo 1200 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Wilate: FVIII 500 units and VWF:RCo 500 units (1 ea); FVIII 1000 units and VWF:RCo 1000 units (1 ea)</p></div>
<div class="block adip drugH1Div" id="F53569451"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">One unit of AHF is equal to the factor VIII activity present in 1 mL of normal human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of AHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large AHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL.</p>
<p style="text-indent:0em;margin-top:2em;">Exact potency varies among products and between lots of the same product; each vial contains the exact labeled amount of VWF activity, as measured with the Ristocetin cofactor activity (VWF:RCo), and factor VIII (FVIII) activity and should be consulted prior to use. However, the average ratio between VWF:RCo and FVIII among available products is:</p>
<p style="text-indent:-2em;margin-left:4em;">Alphanate: Average ratio not provided by manufacturer or in available literature</p>
<p style="text-indent:-2em;margin-left:4em;">Humate-P: Average ratio of VWF:RCo to FVIII is 2.4:1</p>
<p style="text-indent:-2em;margin-left:4em;">Wilate: Average ratio of VWF:RCo to FVIII is ~1:1</p>
<p style="text-indent:0em;margin-top:2em;">Formula to calculate specific in vivo recovery (IVR) is as follows:</p>
<p style="text-indent:0em;margin-left:2em;">IVR (units/dL per units/kg of VWF:RCo administered) = ([Plasma VWF:RCo 30 minutes after infusion (units/dL)] – [Plasma VWF:RCo at baseline (units/dL)] / Dose (units /kg)</p></div>
<div class="block admp drugH1Div" id="F52614206"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Administer through a separate line, do not mix with drugs or other IV fluids. Vasomotor reactions may result from rapid administration. </p>
<p style="text-indent:-2em;margin-left:4em;">Alphanate: Infuse slowly; maximum rate: 10 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">Humate-P: Infuse slowly; maximum rate: 4 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">Wilate: Infuse slowly at a rate of 2 to 4 mL/minute; reduce the rate or interrupt administration in patients who experience a marked increase in pulse rate. </p></div>
<div class="block adm drugH1Div" id="F3000417"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Alphanate: Infuse slowly (maximum rate: 10 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">Humate-P: Infuse slowly (maximum rate: 4 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">Wilate: Infuse slowly at a rate of 2 to 4 mL/minute; reduce the rate of or interrupt administration in patients who experience a marked increase in the pulse rate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Continuous infusion (off-label rate):</b> Has also been administered as a continuous infusion to avoid peaks and troughs associated with intermittent infusions in patients who require prolonged treatment periods. Use a smart infusion pump with small volume infusion capability. Refer to institutional protocols for product selection and preparation details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F3000359"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Products are stable for three years, up to the expiration date printed on the label. For single use; discard any unused contents in vial.</p>
<p style="text-indent:-2em;margin-left:2em;">Alphanate: Store intact vials at ≤25°C (≤77°F); do not freeze. May store reconstituted solution at room temperature (≤30°C). Use within 3 hours of reconstitution; do not refrigerate after reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">Humate-P: Store intact vials at ≤25°C (≤77°F); do not freeze. Once reconstituted, do not refrigerate and use within 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Wilate: Store intact vials under refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze. Store in original container to protect from light. Intact vials may also be stored at room temperature (not to exceed 25°C [77°F]) for ≤6 months. Once stored at room temperature, do not return to the refrigerator. Following reconstitution, use within 4 hours.</p></div>
<div class="block usep drugH1Div" id="F53570055"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Hemophilia A (factor VIII deficiency):</p>
<p style="text-indent:-2em;margin-left:4em;">Alphanate: Prevention and treatment of bleeding episodes in hemophilia A (classic hemophilia); perioperative management of patients with hemophilia A (All indications: FDA approved in ages ≥7 years and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Humate-P: Prevention and treatment of bleeding episodes in hemophilia A (classic hemophilia) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Wilate: On-demand treatment and control of bleeding episodes in hemophilia A; routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A (classic hemophilia) (All indications: FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">von Willebrand disease (VWD):</p>
<p style="text-indent:-2em;margin-left:4em;">Alphanate: Prophylaxis for surgical and/or invasive procedures in patients with VWD when desmopressin is either ineffective or contraindicated (FDA approved in ages ≥7 years and adults). <b>Note:</b> Not indicated for patients with severe VWD undergoing major surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">Humate-P: Treatment of spontaneous and trauma-induced bleeding episodes and prevention of excessive bleeding during and after surgery in patients with mild to moderate and severe VWD where the use of desmopressin is suspected or known to be inadequate (FDA approved in ages ≥1 month and adults). <b>Note:</b> Not indicated for the prophylaxis of spontaneous bleeding episodes.</p>
<p style="text-indent:-2em;margin-left:4em;">Wilate: On-demand treatment and control of bleeding episodes in patients with VWD (FDA approved in ages ≥5 years and adults); perioperative management of bleeding in patients with VWD (FDA approved in all ages).</p></div>
<div class="block mst drugH1Div" id="F11595830"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor VIII may be confused with Factor XIII</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298759"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218025"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F3000347"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant carriers of hemophilia A and those with von Willebrand disease may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor VIII concentrations may increase in pregnant patients; changes in von Willebrand factor levels may vary during pregnancy depending on type. Patients should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. When VWF replacement therapy is needed, a recombinant product or a product made from a safe plasma source with viral testing that contains both factor VIII and von Willebrand factor is recommended. A recombinant product is one of the preferred agents if prophylaxis or treatment is needed for hemophilia A during pregnancy (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53570039"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of intravascular hemolysis or bleeding; heart rate and blood pressure (before and during IV administration); hypersensitivity reactions during the infusion. AHF concentrations prior to and during treatment; in patients with circulating inhibitors, the inhibitor concentration should be monitored; hematocrit; VWF activity (circulating concentrations of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]). In surgical patients, monitor VWF:RCo at baseline and after surgery, trough VWF:RCo and FVIII:C at least daily. Monitor for hypersensitivity reactions during infusion.</p></div>
<div class="block rerp drugH1Div" id="F53569443"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Hemophilia: Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII:C (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F3000361"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;text-align:justify;display:inline">Factor VIII and von Willebrand factor (VWF), obtained from pooled human plasma, are used to replace endogenous factor VIII and VWF in patients with hemophilia or von Willebrand disease. Factor VIII in conjunction with activated factor IX, activates factor X which converts prothrombin to thrombin and fibrinogen to fibrin. VWF promotes platelet aggregation and adhesion to damaged vascular endothelium and acts as a stabilizing carrier protein for factor VIII. (Circulating levels of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]).</p></div>
<div class="block phk drugH1Div" id="F3000404"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Shortening of bleeding time: Immediate.</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum effect: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: von Willebrand disease: Shortening of bleeding time: &lt;6 hours postinfusion; presence of VWF multimers detected in the plasma: ≥24 hours (Alphanate).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Factor VIII activity (in patients with hemophilia A): Wilate: Adult: 0.36 to 0.82 dL/kg; pediatric patients ≥12 years: 0.53 to 0.85 dL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>dss</sub>: VWF:RCo (in patients with von Willebrand disease): Humate: 29 to 290 mL/kg; Wilate: 15 to 160 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Factor VIII coagulant activity (FVIII:C): Range (in patients with hemophilia A): Alphanate: 8 to 28 hours; Humate: 8 to 17 hours; Wilate: Adult: 6.3 to 15.43 hours; pediatric patients ≥12 years: 9.37 to 14.57 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">VWF:RCo: Range (in patients with von Willebrand disease): Alphanate: 4 to 16 hours; Humate: 3 to 34 hours; Wilate: 6 to 49 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F24170861"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Haemate p</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">8y | Haemate p | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Biostate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Wilate</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alphanate | Biostate | Haemate p | Immunate | Immunate s/d | Voncento | Wilate</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Haemate HS | Immunate | Immunate Stim Plus | Voncento | Wilate</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alphanate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dried factor viii fraction + factor de von willebrand | Haemate p | Immunate | Voncento | Wilate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate Stim Plus | Wilate</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Haemate HS | Immunate | Voncento</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dried factor viii fraction, type 8Y</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Wilate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Immunate</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eqwilate | Voncento | Wilstart</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">8y | Alphanate | Dried factor viii fraction, type 8Y | Haemate | Haemate p | Voncento | Wilate</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Haemate p</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aleviate | Alphanate | Biostate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate s/d | Immunate Stim Plus | Wilate</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">8y | Haemate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Wilate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Immunate</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alphanate | Haemate p | Immunate Stim Plus | Wilate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Confact f | Haemate p</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Immunate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Immunate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Wilate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Wilate</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alphanate | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Concentrado de factor VIII | Haemate p</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate | Immunate Stim Plus</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Wilate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Haemate p | Wilate</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Haemate P</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Immunate | Wilate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alphanate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Wilate</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Wilate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alphanate | Immunate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Haemate | Immunate</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate Stim Plus</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alphanate | Haemate p</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Immunate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Immunate | Immunate Stim Plus</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Haemate p | Haemosolvate factor viii</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25930155">
<a name="25930155"></a>Abshire T, Cox-Gill J, Kempton CL, et al. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. <i>J Thromb Haemost.</i> 2015;13(9):1585-1589. doi:10.1111/jth.12995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/25930155/pubmed" id="25930155" target="_blank">25930155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alphanate.1">
<a name="Alphanate.1"></a>Alphanate (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010406">
<a name="12010406"></a>Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177. doi:10.1046/j.1365-2516.2002.00635.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/12010406/pubmed" id="12010406" target="_blank">12010406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530687">
<a name="22530687"></a>Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759. doi:10.1111/j.1365-2516.2012.02810.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/22530687/pubmed" id="22530687" target="_blank">22530687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7843640">
<a name="7843640"></a>Berntorp E, “Plasma Product Treatment in Various Types of von Willebrand Disease,” <i>Haemostasis</i>, 1994, 24(5):289-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/7843640/pubmed" id="7843640" target="_blank">7843640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19149848">
<a name="19149848"></a>Berntorp E and Windyga J, “Treatment and Prevention of Acute Bleeding in von Willebrand Disease -- Efficacy and Safety of Wilate®, A New Generation von Willebrand Factor/Factor VIII Concentrate,” <i>Haemophilia</i>, 2009, 15(1):122-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/19149848/pubmed" id="19149848" target="_blank">19149848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18786010">
<a name="18786010"></a>Berntorp E. Prophylaxis in von Willebrand disease. <i>Haemophilia</i>. 2008;14(suppl 5):47-53. doi:10.1111/j.1365-2516.2008.01851.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/18786010/pubmed" id="18786010" target="_blank">18786010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33570647">
<a name="33570647"></a>Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. <i>Blood Adv</i>. 2021;5(1):301-325. doi:10.1182/bloodadvances.2020003264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/33570647/pubmed" id="33570647" target="_blank">33570647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19811543">
<a name="19811543"></a>Federici AB, Barillari G, Zanon E, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. <i>Haemophilia</i>. 2010;16(1):101-110. doi:10.1111/j.1365-2516.2009.02088.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/19811543/pubmed" id="19811543" target="_blank">19811543</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Federici AB, “Clinical Diagnosis of von Willebrand's Disease,” <i>Haemophilia</i>, 2004, 10(Suppl 4):169-76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25688461">
<a name="25688461"></a>Holm E, Abshire TC, Bowen J, et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. <i>Blood Coagul Fibrinolysis</i>. 2015;26(4):383-388. doi:10.1097/MBC.0000000000000257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/25688461/pubmed" id="25688461" target="_blank">25688461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28873263">
<a name="28873263"></a>Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. <i>Haemophilia</i>. 2018;24(1):24-32. doi:10.1111/hae.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/28873263/pubmed" id="28873263" target="_blank">28873263</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Humate-P (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Kankakee, IL: CSL Behring; June 2020.</div>
</li>
<li>
<div class="reference">
                  Humate-P (antihemophilic factor/von Willebrand factor complex [human]) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7843642">
<a name="7843642"></a>Kreuz W, Mentzer D, Becker S, et al, “Haemate P in Children With von Willebrand's Disease,” <i>Haemostasis</i>, 1994, 24(5):304-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/7843642/pubmed" id="7843642" target="_blank">7843642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10063997">
<a name="10063997"></a>Lubetsky A, Schulman S, Varon D, et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. <i>Thromb Haemost</i>. 1999;81(2):229-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/10063997/pubmed" id="10063997" target="_blank">10063997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1482660">
<a name="1482660"></a>Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. <i>Br J Haematol</i>. 1992;82(4):729-734. doi:10.1111/j.1365-2141.1992.tb06951.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/1482660/pubmed" id="1482660" target="_blank">1482660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute (NHLBI). The Diagnosis, Evaluation, and Management of von Willebrand Disease. NIH Publication No. 08-5832. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood, 2007.</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (MASAC Document 253). https://www.hemophilia.org/sites/default/files/document/files/masac253.pdf. Published April 2018. Accessed June 12, 2018.</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation. MASAC recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at http://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Peterson CW, “Treating Hemophilia,” <i>Am Pharm</i>, 1994, NS34(8):57-67.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30747707">
<a name="30747707"></a>Peyvandi F, Castaman G, Gresele P, et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. <i>Blood Transfus</i>. 2019;17(5):391-398. doi:10.2450/2019.0183-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/30747707/pubmed" id="30747707" target="_blank">30747707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503305">
<a name="22503305"></a>Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/22503305/pubmed" id="22503305" target="_blank">22503305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27214734">
<a name="27214734"></a>Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/27214734/pubmed" id="27214734" target="_blank">27214734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7843641">
<a name="7843641"></a>Scharrer I, Vigh T, and Aygoren-Purun E, “Experience With Haemate P in von Willebrand's Disease in Adults,” <i>Haemostasis</i>, 1994, 24(5):298-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/7843641/pubmed" id="7843641" target="_blank">7843641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11307831">
<a name="11307831"></a>White GC, Rosendaal F, Aledort LM, et al, “Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,” <i>Thromb Haemost</i>, 2001, 85(3):560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/11307831/pubmed" id="11307831" target="_blank">11307831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilate.1">
<a name="Wilate.1"></a>Wilate (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; December 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13397 Version 209.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
